Search

Displaying results 2691 - 2700 of 6951 in total
  1. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    Sebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293]. … Food and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538].

  2. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  3. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. … The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol.

  4. Drug

    Estradiol valerate

    go.drugbank.com/drugs/DB13956
    ApprovedInvestigationalVet approved

    due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation … Estradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.

    Categories: Hormonal Contraceptives for Systemic Use
  5. Drug

    Phylloquinone

    go.drugbank.com/drugs/DB01022
    ApprovedInvestigational

    Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin. Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X. It is indicated ...

    Mixtures: Vitalipid - Vitaminkonzentrat zur Infusionsbereitung für Kinder, Vitalipid - Vitaminkonzentrat zur Infusionsbereitung für Erwachsene
  6. Drug

    Bumadizone

    go.drugbank.com/drugs/DB13286
    Approved

    Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis

  7. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    It is originally native to China, and _ginkgo biloba_ extract has been used in traditional Chinese medicine for centuries. … [A232384] _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    RESP301 was under investigation in clinical trials for various conditions. … Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor

  10. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]